-+ 0.00%
-+ 0.00%
-+ 0.00%

BioDlink shareholders vote June 11 on WuXi XDC CDMO services pact with RMB 424.8 million 2028 cap

PUBT·05/26/2026 12:50:55
Listen to the news
BioDlink shareholders vote June 11 on WuXi XDC CDMO services pact with RMB 424.8 million 2028 cap
  • TOT Biopharm shareholders will vote on a continuing connected transaction framework, the CDMO Master Services Agreement with controlling shareholder WuXi XDC.
  • The deal would have TOT Biopharm provide bioconjugate-drug CDMO services under project-based service contracts, subject to independent shareholder approval.
  • Proposed annual caps: RMB 92.5 million for 2026, RMB 257.1 million for 2027, RMB 424.8 million for 2028.
  • The extraordinary general meeting is scheduled for June 11, 2026.
  • The board and the independent board committee recommend voting in favor of the resolution.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260526-12171514), on May 26, 2026, and is solely responsible for the information contained therein.